ESMO Annual Meeting
October 17 – 21, 2025 | Berlin, Germany

As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access. This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.

Content to be used in accordance with local CPO guidelines

Prostate Cancer

Prostate Cancer

List of Presentations

Breast Cancer Prostate Cancer NET Small Cell Lung Cancer Non-Small Cell Lung Cancer Thyroid Cancer Advanced Solid Tumors Melanoma

Phase 3 Trial of [177Lu]Lu-PSMA-617 Combined With ADT + ARPI in Patients With PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition)

Scott T. Tagawa, Oliver Sartor, Josep M. Piulats, Fred Saad, Karim Fizazi, Alison Reid, Himisha Beltran, Gero Kramer, Hakim Mahammedi, Matthias Eiber, Shilpa Gupta, Daniel Castellano, Ralph Hauke, Hyun Kim, Cheol Kwak, See Tong Pang, Emmanuel Bouillaud, Angela Zhang, Olga Sakharova, Michael J. Morris

  • Oral/Presidential Symposium Presentation #LBA6
    Berlin Auditorium - Hub 27 | Sunday, October 19, 2025 | 17:14-17:24 CEST (Presidential Symposium/Oral Presentation) | 17:56-18:15 CEST (Discussion)

  • Abstract
This presentation will be available once the congress embargo lifts

Associations Between Quantitative Baseline 68Ga-PSMA-11 PET Parameters and 177Lu-PSMA-617 Efficacy in the PSMAfore Study

Ken Herrmann, Kim N. Chi, Johann S. de Bono, Karim Fizazi, Oliver Sartor, Xiao X. Wei, James Nagarajah, Matthias Eiber, Irene A. Burger, Phillip H. Kuo, Samson Ghebremariam, Nisha Rajagopal, Connie C. Wong, Shaheen Alanee, Michael J. Morris

  • Poster Presentation #2390P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts

Access to 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) in France: Comparative Analysis With Cabazitaxel Using National Hospital Data

Denis Maillet, Barbara Roux, Jade Vadel, Aurore Tricotel, Donatien Collet, Camille Wiart, Quentin Dardonville, Elske Quak

  • Poster Presentation #2415P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts

PSMACare Trial-in-Progress: A Phase 2 Trial of [177Lu]Lu-PSMA-617 With or Without ARPI in Patients With PSMA-Positive Non-Metastatic Castration-Resistant Prostate Cancer

Fred Saad, Javier Puente, Jeremie Calais, Mark Fleming, Anne-Laure Louveau, Fazia Brouri, Mariana Carbini, Alicia Morgans

  • e-Poster Presentation #2537eTiP
    Hall 25 | Saturday, October 18, 2025 (e-poster)

  • Abstract
This presentation will be available once the congress embargo lifts

Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France

Vincent Massard, Clément Bailly, Pierre Olivier, Lavinia Vija, Anne-Laure Giraudet, Guilhem Roubaud, Sylvie Girault, Sophie Abadie-Lacourtoisie, Caroline Viala, Aude Flechon, Stéphanie Chêne, Yann Godbert

  • Poster Presentation #2389P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts

Retreatment with [177Lu]Lu-PSMA-617 in mCRPC patients treated under the French Early Access Program (EAP)

Philippe Barthélémy, David Taieb, François Somme, Corentin Peltier, Stéphanie Chêne, Alix Douillet, Philippe Robin

  • Poster Presentation #2395P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts

PSMAcTION Trial-in-Progress: A Phase 2/3 Randomized Trial of [225Ac]Ac-PSMA-617 Versus Standard of Care in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer who progressed on or After [177Lu]Lu-PSMA therapy

Louise Emmett, Matthias Eiber, Oliver Sartor, Neal Shore, Xiao X. Wei, Xiaohong Li, Praseeda Thaikalloor, Liane Pinto, Mike Sathekge

  • Poster Presentation #2516TiP
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts

Identification of a Novel Cluster of Patients With Prostate Cancer in Japan With Improved Quality of Life – Results of the Largest International Digital Survey of People Affected by Prostate Cancer

Hiroji Uemura, Reiner Lehmann, Hiroya Saito, Kazuyuki Suzuki, Vivienne Beckett, Osvaldo Mirante, Joe M. O’Sullivan, Alicia K. Morgans

  • Poster Presentation #2474P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

  • Abstract
This presentation will be available once the congress embargo lifts
View list of select presentations for this compound